1
TÍTULO: Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
AUTORES: Valeria Santini; Antonio Almeida; Aristoteles Giagounidis; Stefanie Groepper; Anna Jonasova; Norbert Vey; Ghulam J Mufti; Rena Buckstein; Moshe Mittelman; Uwe Platzbecker; Ofer Shpilberg; Ron Ram; Consuelo del Canizo; Norbert Gattermann; Keiya Ozawa; Alberto Risueno; Kyle J MacBeth; Jianhua H Zhong; Francis Seguy; Albert Hoenekopp; Beach, CL; Pierre Fenaux; ...Mais
PUBLICAÇÃO: 2016, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 34, NÚMERO: 25
INDEXADO EM: Scopus WOS CrossRef
2
TÍTULO: Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
AUTORES: Valeria Santini; Antonio Almeida; Aristoteles Giagounidis; Stephanie Groepper; Anna Jonasova; Norbert Vey; Ghulam J Mufti; Rena Buckstein; Moshe Mittelman; Uwe Platzbecker; Ofer Shpilberg; Ron Ram; Consuelo del Canizo; Norbert Gattermann; Keiya Ozawa; Jim Zhong; Francis Seguy; Albert Hoenekopp; Beach, CL; Pierre Fenaux;
PUBLICAÇÃO: 2014, FONTE: 56th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 124, NÚMERO: 21
INDEXADO EM: WOS